-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the 5th China International Import Expo, Novo Nordisk (Shanghai) Pharmaceutical Trading Co.
, Ltd.
(hereinafter referred to as "Novo Nordisk Shanghai") signed a strategic cooperation agreement with Shanghai Pharmaceutical Holdings Co.
, Ltd
.
(hereinafter referred to as "Shanghai Pharmaceutical Holdings").
Through innovative pharmaceutical third-party logistics services, Shanghai Pharmaceutical Holdings will provide Novo Nordisk Shanghai with intelligent modern logistics warehouses, and further meet the future business development needs of Novo Nordisk Shanghai with intensive, standardized, informationized and intelligent pharmaceutical logistics management and operations, and help Novo Nordisk better serve Chinese patients
.
Zhang Qing, Deputy Director of Shanghai Food and Drug Administration, said that this cooperation is fully innovative, forward-looking and exemplary, which is a useful exploration for Shanghai Pharmaceutical Holdings to cooperate with industry partners to participate in the global medical industry and integrate into the international and domestic dual circulation, and it is also an important measure
to help Shanghai further play a leading role in the biomedical industry and accelerate the construction of an innovation highland of the biopharmaceutical industry with international influence.
Zhang Qing hopes that Shanghai Pharmaceutical Holdings and Novo Nordisk will build the cooperation project into a bright business card of Lingang New Area and contribute to the new round of high-quality development of
Shanghai's biomedical industry.
Li Yongzhong, executive director and vice president of Shanghai Pharmaceutical and general manager of Shanghai Pharmaceutical Holdings, said that in the past 20 years, Shanghai Pharmaceutical Holdings has participated in a number of blockbuster products
of Novo Nordisk.
As a result of these efforts, the cooperation between the two sides has been growing
steadily.
The signing of this strategic cooperation will be an innovative breakthrough
in the tripartite logistics of pharmaceuticals for both parties.
Xiaping Zhou, Senior Vice President and President of Greater China, Novo Nordisk, said: "This investment is an important step for Novo Nordisk to realize the new layout of the 'dual center, three engines' whole industry chain, which will further strengthen the business capabilities of the trade and innovation center in Shanghai, support the development of Shanghai's pharmaceutical trade, and better serve Chinese patients
.
" "Dual Center, Triple Engine" refers to Novo Nordisk's Greater China Trade and Innovation Center in Shanghai, Greater China Production Center in Tianjin, and R&D Engine in China in Beijing
.
Since entering China in 1994, Novo Nordisk has established a whole industrial chain layout integrating R&D, production and operation
.
In the five years since its participation in the Expo, Novo Nordisk has invested in China five times, with a total investment of more than 2.
5 billion yuan
.
(End)
, Ltd.
(hereinafter referred to as "Novo Nordisk Shanghai") signed a strategic cooperation agreement with Shanghai Pharmaceutical Holdings Co.
, Ltd
.
(hereinafter referred to as "Shanghai Pharmaceutical Holdings").
Through innovative pharmaceutical third-party logistics services, Shanghai Pharmaceutical Holdings will provide Novo Nordisk Shanghai with intelligent modern logistics warehouses, and further meet the future business development needs of Novo Nordisk Shanghai with intensive, standardized, informationized and intelligent pharmaceutical logistics management and operations, and help Novo Nordisk better serve Chinese patients
.
Zhang Qing, Deputy Director of Shanghai Food and Drug Administration, said that this cooperation is fully innovative, forward-looking and exemplary, which is a useful exploration for Shanghai Pharmaceutical Holdings to cooperate with industry partners to participate in the global medical industry and integrate into the international and domestic dual circulation, and it is also an important measure
to help Shanghai further play a leading role in the biomedical industry and accelerate the construction of an innovation highland of the biopharmaceutical industry with international influence.
Zhang Qing hopes that Shanghai Pharmaceutical Holdings and Novo Nordisk will build the cooperation project into a bright business card of Lingang New Area and contribute to the new round of high-quality development of
Shanghai's biomedical industry.
Li Yongzhong, executive director and vice president of Shanghai Pharmaceutical and general manager of Shanghai Pharmaceutical Holdings, said that in the past 20 years, Shanghai Pharmaceutical Holdings has participated in a number of blockbuster products
of Novo Nordisk.
As a result of these efforts, the cooperation between the two sides has been growing
steadily.
The signing of this strategic cooperation will be an innovative breakthrough
in the tripartite logistics of pharmaceuticals for both parties.
Xiaping Zhou, Senior Vice President and President of Greater China, Novo Nordisk, said: "This investment is an important step for Novo Nordisk to realize the new layout of the 'dual center, three engines' whole industry chain, which will further strengthen the business capabilities of the trade and innovation center in Shanghai, support the development of Shanghai's pharmaceutical trade, and better serve Chinese patients
.
" "Dual Center, Triple Engine" refers to Novo Nordisk's Greater China Trade and Innovation Center in Shanghai, Greater China Production Center in Tianjin, and R&D Engine in China in Beijing
.
Since entering China in 1994, Novo Nordisk has established a whole industrial chain layout integrating R&D, production and operation
.
In the five years since its participation in the Expo, Novo Nordisk has invested in China five times, with a total investment of more than 2.
5 billion yuan
.
(End)
